Table 1.
Baseline characteristics of HIV infected mothers and time of earliest antiretroviral therapy during pregnancy
| Characteristics | First trimester (n = 329) | Second/third trimester (n = 488) | No antiretroviral treatment (n = 80) | P |
|---|---|---|---|---|
| Mean age (y) (n = 825) | 33.3 | 30.3 | 29.8 | <0.001 |
| Race (n = 898) | < 0.001 | |||
| Caucasian | 279 (84.8%) | 307(62.9%) | 41 (51.2%) | |
| Sub-Saharan | 33 (10.0%) | 95 (19.5%) | 27 (33.7%) | |
| Latino American | 13 (4.0%) | 74 (15.2%) | 9 (11.2%) | |
| Others | 4 (1.2%) | 12 (2.4%) | 3 (3.8%) | |
| Smoking during pregnancy | 123 (41.8%) | 136 (30.8%) | 11 (16.1%) | 0.05 |
| Alcohol use during pregnancy (n = 696) | 10 (3.6%) | 16 (4.4%) | 8 (16.3%) | < 0.001 |
| Illegal drug use during pregnancy (n = 750) | 22 (7.4%) | 35 (8.9%) | 17 (27.9%) | < 0.001 |
| CD4+ lymphocyte count at enrolment (n = 554) | 0.61 | |||
| >500 cells/μl | 121 (48.2%) | 123 (42.7%) | 6 (40%) | |
| 200-500 cells/μl | 103 (41.0%) | 127 (44.1%) | 8 (53.3%) | |
| <200 cells/μl | 27 (10.8%) | 38 (13.2%) | 1 (6.7%) | |
| HIV RNA levels to delivery (n = 642) | <0,001 | |||
| <50 copies /ml | 224 (81.4%) | 245 (70.6%) | ||
| >50 copies/ml | 51 (18.6%) | 102 (29.4%) | 20 (100%) |